Sunday, April 17
P2.153 Multiple Sclerosis, EDSS
and Walking: Computerized Objective Gait Analysis of the Impact of a 6-Minute Timed Walk on Selected Gait Characteristics in People with Multiple Sclerosis - Putting Long Legs on a Walking Scale —Christina Burke, Mark Gudesblatt, Karl Wissemann, Myassar Zarif, Barbara Bumstead, Lori Fafard, Smitha Thotam, John Magel, Marijean Buhse, Lisa Muratori
P2.154 Improving MS Care with an
International Videoconference-Based Provider Education and Case Consultation Program —Kevin Alschuler, Annette Wundes, Dennis Dietrich, Boskovski Bojan, Igor Kuzmanovski, Gloria Von Geldern, Katharine Alexander, Gary Stobbe
P2.155 Does MRZ Reaction Have
a Real Significance in the Diagnosis of Multiple Sclerosis? —Pavel Hradilek, David Zeman, Barbora Kurkova, Olga Zapletalova, Ivana Woznicova, Katarina Reguliova, Radim Piza
P2.156 A Qualitative Assessment
of Key Symptoms Associated with the Progression from RRMS to SPMS by Physicians and Patients —Bryan Bennett,
Chloe Tolley, Sarah Kilgariff, Deniz Simsek, Raquel Lahoz, Elisabetta Verdun Di Cantogno, Tjalf Ziemssen
P2.157 The Relationship Between the
Clinical Condition of MS Patients and the Nutritional Status, Mitochondrial Activity and Oxidative Stress —Radi Shahien, Chen Waldman, Ayelet Omer Armon
MS and CNS Inflammatory Disease: Treatment of NMO and Other CNS Diseases
P2.158 Does Rituximab Cause
Depletion of T-Cells in Multiple Sclerosis and Neuromyelitis Optica? —Paula Hardeman, Martha Mann, Samuel Hughes, Benjamin Greenberg
P2.159 A Phase 1b Clinical Trial with
Tolerogenic Dendritic Cells for Multiple Sclerosis and Neuromyelitis Óptica —Irati
Zubizarreta, Daniel Benitez, Varea Sara, Joan Albert Arnaiz, Albert Saiz, Pablo Villoslada
P2.160 Long-term Effect of
Cyclosporine A in the Prophylaxis of Neuromyelitis Optica Spectrum Disorders —Takashi Kageyama, Katsuichi
Miyamoto, Akihiko Ozaki, Mika Komori, Taro Okunomiya, Daisuke Kambe, Toshihiko Suenaga, Susumu Kusunoki, Sadayuki Matsumoto, Ryosuke Takahashi, Takayuki Kondo
P2.161 Infliximab for Treatment
Refractory Neuro-Behçet Syndrome — Burcu Zeydan, Ugur Uygunoglu, Sabahattin Saip, Onat Demirci, Emire Seyahi, Serdal Ugurlu, Vedat Hamuryudan, Aksel Siva, Orhun Kantarci
P2.162 Induction of Autoimmune
Encephalitis by Treatment with Ipilimumab and Nivolumab —David Benavides, Tanya Williams, Kelly-Ann Patrice, Dung Le, Evan Lipson, Ellen Mowry, John Probasco
Poster Session 8:30 a.m.–5:30 p.m.
P2.163 Treatment of Anti-DPPX-
P2.174 Aerobic Exercise Improves
P2.187 Allergies Are Associated with
Andrew Smith, Andrew Goodman, Andrew McKeon, Lawrence Samkoff
Spain, Manoj Sammi, Bharti Garg, Rebecca Kingsland, Kerry Kuehl, William Rooney
Brian Healy, Neda Sattarnezhad, Bonnie Glanz, Howard Weiner, Tanuja Chitnis
Encephalitis Refractory to Corticosteroids, Plasma Exchange and Rituximab —
Fitness and Cognition in Relapsing Remitting Multiple Sclerosis —Rebecca
P2.164 Infliximab for the Treatment
P2.175 Which Symptoms Correlate
James Utz
P2.176 The Association of Pathological
of Neurosarcoidosis: The Mayo Clinic Experience —Derek Stitt, Allen Aksamit,
P2.165 Rituximab for Refractory
Myasthenia Gravis in a Pregnant Patient —Tarun Girotra, Nour Baki, Kavita Grover
P2.166 Case Report: Improvement
of GAD65-Associated Autoimmune Epilepsy with Testosterone Replacement Therapy —Melissa Heiry, Pegah Afra, Fumisuke Matsuo, John Greenlee, Stacey Clardy
P2.167 A Case of Sarcoidosis
with Improvement After Initiation of Natalizumab Therapy —Josef Gutman, Jerome Graber, David Dickoff
MS and CNS Inflammatory Disease: MS Symptoms, Specific Symptoms Treatments, Co-morbidities, and Cost
P2.168 Cognitive Impairment in Newly Diagnosed Multiple Sclerosis: Does It Differ Between Racial/Ethnic Groups? —
Christopher Schroeder, Edlin Gonzales, Samantha Haraszti, Annette Langer-Gould
P2.169 Clinical Response to
Nabiximols (Sativex®) on Spasticity and Pain Is Paralleled by a Down-Regulation of Immune-Related Pathways in Multiple Sclerosis Patients —Filippo Martinelli Boneschi, Melissa Sorosina, laura ferre', Ferdinando Clarelli, Vittorio Martinelli, Federica Esposito, Giancarlo Comi
P2.170 An Adaptive Computer-Based
Cognitive Training Program Improves Cognitive Functioning in Adults with Multiple Sclerosis (MS): Results of a Double-Blind Randomized Active-PlaceboControlled 12-Week Trial —Leigh Charvet, Jie Yang, Michael Shaw, Kathleen Sherman, Jianjin Xu, Lamia Haider, Lauren Krupp
P2.171 Dialectical Behaviour Therapy Is an Effective Treatment for Depression and Anxiety in Multiple Sclerosis —
Mervin Blair, Sascha Gill, Denise Deluca, Grace Ferreria, Rebecca King, Andrew Ekblad, Denise Bowman, Joshua Hanna, Kathy Smolewska, Erin Warriner, Sarah Morrow
P2.172 Elevated Brain Temperature
Is Associated with Worse Fatigue in Relapsing Remitting Multiple Sclerosis Patients —Victoria Leavitt, Alayar Kangarlu, Feng Liu, Claire Riley, James Sumowski
P2.173 Multiple Sclerosis, Fatigue and Discordant Patient Reported Outcomes: Sleep Quality (Sleep-NeuroQoL), Neurological Disability and Depression —
Mark Gudesblatt, Karl Wissemann, Myassar Zarif, Barbara Bumstead, Lori Fafard, Cynthia Sullivan, Jeffrey Wilken, Marijean Buhse, Daniel Golan
the Most to Health-Related Quality of Life (HRQoL) in MS? —Rivka Green, Ilya Kister Laughing and Crying and Cognitive Impairment in Multiple Sclerosis —Joshua Hanna, Anthony Feinstein, Sarah Morrow
P2.177 Successful Treatment of
Paroxysmal Ataxia and Dysarthria in MS with Levitracetam —Shikha Goodwin, Adam Carpenter
P2.178 Gender Identity Disorders
and Multiple Sclerosis Risk: A National Record-Linkage Study —Julia Pakpoor,
Clare Wotton, Klaus Schmierer, Gavin Giovannoni, Michael Goldacre
P2.179 Assessment of Olfaction and Gustation in Multiple Sclerosis: Correlation with Cognition —Ozgul
Ekmekci, Naila Alakbarova, Ayse Nur Yuceyar
P2.180 Antidepressant Use in
Association with Multiple Sclerosis Disease Modifying Therapy —Matthew
Mirsky, Alexander Rae-Grant
P2.181 Association of Disability
Progression and Affective Disorders over Time in a Prospective 9 Year Follow Up Cohort of Patients with Multiple Sclerosis —Matthias Knop, Sandra Nischwitz, Marcus Ising, Hans Faber, Frank Weber
P2.182 Improvement of the
Spatiotemporal Parameters in Walking in Primary Progressive Patients Treated with Fampridine —Ines Gonzalez, Irene
Increased Disease Activity in Multiple Sclerosis —Camilo Diaz-Cruz, Alicia Chua,
P2.188 Persistent Use of
Dalfampridine Extended Release on Healthcare Resource Utilization and Cost in Multiple Slerosis: A Claims Database Analysis —Stephen Krieger, Alexander
Niyazov, Dendy Macaulay, Emi Terasawa, Eric Wu, Peter Aupperle, Amy Guo
P2.189 Hereditary Neuropathy with
Liability to Pressure Palsies (HNPP) and Multiple Sclerosis (MS) in the Same Patient: Coincidence or Link? —Nassima Baba-Ahmed, Aram Zabeti, Hani Kushlaf
P2.190 Age-, Sex-, and Geographic
Region-Specific Comorbidity in Patients with Multiple Sclerosis —Natalie Edwards,
Amy Phillips, Julie Locklear
P2.191 Suicide Ideation in Multiple Sclerosis —Aliza Ben-Zacharia
P2.192 Sick Leave and Disability
Pension in Patients with Multiple Sclerosis: A Longitudinal, Observational Study —Erik Landfeldt, Anna Castelo-
Branco, Axel Svedbom, Emil Lofroth, Andrius Kavaliunas, Jan Hillert
P2.193 Cost Effectiveness of Multiple Sclerosis Therapeutic Strategies for Achieving No Evidence of Disease Activity —Daniel Ontaneda, Olaisen Henry
P2.194 Dynamic Hand Grip Objectively Measures Fatigue in Multiple Sclerosis (MS) and Improves with Transcranial Direct Current Stimulation (tDCS) —
Raghav Malik, Margaret Kasschau, Michael Shaw, Michael Porter, Colleen Schwarz, Leigh Charvet
Pulido-Valdeolivas, David Gomez-Andres, Aida Orviz-Garcia, Andrea Montero-Atalaya, Juan Andres Martin-Gonzalo, Irene Rodriguez-Andonaegui, Estrella Rausell, Celia Oreja-Guevara
P2.195 Effects of a Program Designed
P2.183 Sexual Dysfunction in Male
P2.196 Concepts Important for
Patients with Multiple Sclerosis —lorena
garcia, Alba Velazquez, Elena Bellosta Diago, Sonia Santos, Cristina Iniguez
P2.184 Psychological Growth and
to Improve Self-Efficacy and Subsequent Effects on Decreasing Loneliness and Depression Among People with Multiple Sclerosis —Jennifer Kalina Multiple Sclerosis Patient Caregivers: Systematic Literature Review of Qualitative Studies —Sarah Naoshy, Jie Ting, Crystal Watson, Delphine Jurado, Catherine Acquadro, Isabelle Savre
Benefit Finding in Multiple Sclerosis (MS) and Their Relationship to Symptom Burden —Allison Marziliano, Kathleen
P2.197 Lower Socioeconomic Status Is
P2.185 Examining the Effects of
Maria Rocca, Victoria Leavitt, Alessandro Meani, Sarlota Mesaros, Jelena Drulovic, Paolo Preziosa, Giancarlo Comi, Massimo Filippi
Sherman, Michael Shaw, Ariana Frontario, Leigh Charvet
Comorbidities on Disease-Modifying Therapy Use in Multiple Sclerosis —
Tingting Zhang, Helen Tremlett, Stella Leung, Feng Zhu, Elaine Kingwell, John Fisk, Virender Bhan, Trudy Campbell, Nancy Yu, Ruth-Ann Marrie
P2.186 Parkinson’s Disease in
Multiple Sclerosis - A Population-Based, Nationwide Study in Denmark —Anja Thormann, Melinda Magyari, Nils KochHenriksen, Bjarne Laursen, Per SoelbergSorensen
Linked to Worse Disability in Persons with Multiple Sclerosis —James Sumowski,
Headache: Therapeutics
P2.198 Cost-Effectiveness of Initial
Prophylactic Treatment of Chronic Migraine: Oral Medications Versus OnabotulinumtoxinA —Kristin Kelley, Anna Schoenbrunner, James Murphy
P2.199 Short-Term Non-Invasive
Vagus Nerve Stimulation (nVNS) for the Prevention of Menstrual Migraine —Licia
Grazzi, Gabriella Egeo, Anna Padovan, Eric Liebler, Piero Barbanti
50 2016 AAN Annual Meeting Abstract Listing